Changes to the intermediate filament (IF) protein, vimentin, were found to promote tumor growth by increasing cancer stemness in an oestrogen independent manner. Targeting vimentin and/or the long noncoding RNA (lncRNA) ‘XIST’ could be an effective therapeutic strategy for treating aggressive breast cancer.
